Buysiders eye 2022 as the year of immuno-oncology’s next big act

Cancer immunotherapy is poised for long-awaited breakthroughs in 2022, which promises a full slate of regulatory and clinical milestones that could re-ignite buysider excitement while drawing in generalists.

For the last seven years, the immuno-oncology market has remained dominated by the first PD-1 blockers to gain approval, despite a massive influx of new companies and pharma resources aimed at identifying the next immunotherapy success story...